Literature DB >> 21450932

A method to quantify illicit intake of drugs from urine: methamphetamine.

Linghui Li1, Gantt P Galloway, Davide Verotta, E Thomas Everhart, Matthew J Baggott, Jeremy R Coyle, Juan C Lopez, John Mendelson.   

Abstract

Qualitative urinalysis can verify abstinence of drug misuse but cannot detect changes in drug intake. For drugs with slow elimination, such as methamphetamine (MA), a single episode of abuse can result in up to 5 days of positive urine drug screens. Thus, interventions that produce substantial decreases in drug use but do not achieve almost complete abstinence are classified as ineffective. Using nonpharmacologic doses of deuterium-labeled l-methamphetamine (l-MA-d(3)) we have developed a simple, robust method that reliably estimates changes in MA intake. Twelve subjects were dosed with 5 mg of l-MA-d(3) daily and challenged with 15, 30, and 45 mg of nonlabeled d-MA (d-MA-d(0)) after reaching plasma steady status of l-MA-d(3). Urinary concentration ratios of d-MA-d(0) to l-MA-d(3) provided clear separation of the administered doses with as little as 15-mg dose increments. Administered doses could not be resolved using d-MA-d(0) concentrations alone. In conclusion, the urinary [d-MA-d(0)]:[l-MA-d(3)] provides a quantitative, continuous measure of illicit MA exposure. The method reliably detects small, clinically relevant changes in illicit MA intake from random urine specimens, is amenable to deployment in clinical trials, and can be used to quantify patterns of MA abuse.

Mesh:

Substances:

Year:  2011        PMID: 21450932      PMCID: PMC3126645          DOI: 10.1124/jpet.111.179176

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  14 in total

1.  Methamphetamine quantitative urine concentrations during a controlled trial of fluoxetine treatment. Preliminary analysis.

Authors:  S L Batki; J Moon; K Delucchi; M Bradley; D Hersh; S Smolar; M Mengis; E Lefkowitz; D Sexe; L Morello; T Everhart; R T Jones; P Jacob
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

2.  An overview of the use of urine, hair, sweat and saliva to detect drug use.

Authors:  Kate Dolan; David Rouen; Jo Kimber
Journal:  Drug Alcohol Rev       Date:  2004-06

Review 3.  Focus on alcohol & drug abuse: ensuring validity in urine drug testing.

Authors:  William B Jaffee; Elisa Trucco; Christian Teter; Sharon Levy; Roger D Weiss
Journal:  Psychiatr Serv       Date:  2008-02       Impact factor: 3.084

4.  Assessment of cocaine use with quantitative urinalysis and estimation of new uses.

Authors:  K L Preston; K Silverman; C R Schuster; E J Cone
Journal:  Addiction       Date:  1997-06       Impact factor: 6.526

5.  Estimating the intake of abused methamphetamines using experimenter-administered deuterium labeled R-methamphetamine: selection of the R-methamphetamine dose.

Authors:  Linghui Li; Juan Carlos Lopez; Gantt P Galloway; Matthew J Baggott; Tom Everhart; John Mendelson
Journal:  Ther Drug Monit       Date:  2010-08       Impact factor: 3.681

6.  Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride.

Authors:  C E Cook; A R Jeffcoat; J M Hill; D E Pugh; P K Patetta; B M Sadler; W R White; M Perez-Reyes
Journal:  Drug Metab Dispos       Date:  1993 Jul-Aug       Impact factor: 3.922

Review 7.  The rise of methamphetamine in Southeast and East Asia.

Authors:  Rebecca McKetin; Nicholas Kozel; Jeremy Douglas; Robert Ali; Balasingam Vicknasingam; Johannes Lund; Jih-Heng Li
Journal:  Drug Alcohol Rev       Date:  2008-05

8.  GC-MS determination of amphetamine and methamphetamine in human urine for 12 hours following oral administration of dextro-methamphetamine: lack of evidence supporting the established forensic guidelines for methamphetamine confirmation.

Authors:  J L Valentine; G L Kearns; C Sparks; L G Letzig; C R Valentine; S A Shappell; D F Neri; C A DeJohn
Journal:  J Anal Toxicol       Date:  1995 Nov-Dec       Impact factor: 3.367

Review 9.  Smokable ("ice", "crystal meth") and non smokable amphetamine-type stimulants: clinical pharmacological and epidemiological issues, with special reference to the UK.

Authors:  Fabrizio Schifano; John M Corkery; Giulio Cuffolo
Journal:  Ann Ist Super Sanita       Date:  2007       Impact factor: 1.663

10.  The bioavailability of intranasal and smoked methamphetamine.

Authors:  Debra S Harris; Harold Boxenbaum; E Thomas Everhart; Gina Sequeira; John E Mendelson; Reese T Jones
Journal:  Clin Pharmacol Ther       Date:  2003-11       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.